First glowing testimonial from Sahlgrenska university hospital
June 2020

Following the CE-marking of Wirecath, it was successfully used in two clinical cases by Dr. Oskar Angerås and RN Fanny Töpel at the Sahlgrenska University Hospital in Gothenburg

The first case was a regular FFR measurement that was easily executed. In the second case, both a sensor-tipped wire and a Wirecath was used to evaluate the distal LAD in a male patient. The distal pressure measurement by the sensor-tipped wire showed a 5mmHg lower value than the Wirecath, both at rest and hyperemia. Hydrostatic error in the sensor-tipped wire was the likely cause, as distal LAD produces an average hydrostatic error of 4mmHg according to published studies.

Coronary flow reserve, CFR, was measured using thermodilution and the result was 3,4. CFR was also calculated based on the Wirecath pressure measurements and the result was 4.

Dr. Angerås stated after the procedures: “The Wirecath is easy to setup and use as a regular pressure wire. It has also the potential to ad specific value by being more accurate in regular pressure measurements, allowing a straightforward pressure-derived CFR measurement that is not possible with any of the currently available pressure wires. This potential will be further evaluated in an upcoming clinical study.”

CE marking cleared of the pressure guidewire Wirecath 1!
June 2020

Enhancing patients’ life

With passionate collaboration and enthusiastic engineering thriving to create the best pressure guidewire on the market, Cavis has completed the realisation of its very first device.

We are enormously proud to announce the clearance of our medical device Wirecath 1 for the European market.

ISO 13485 Certification
September 2019

Cavis quality commitment

Quality is a defining priority at Cavis. Our quality system is designed to comply with ISO 13485:2016 Medical devices – Quality Management Systems. We now have received a certification from our notified body TÜV SÜD. Please find the certificate here.

Co-funded by the Horizon 2020 programme of the European Union
June 2019

EIC Accelerator Pilot supports Cavis

The EIC Accelerator Pilot provides funding for European Start-ups with breakthrough innovations and Cavis was selected for a business innovation grant! The received grant of 50k€ will further boost Cavis growth and pave the way for future scale-up.

Presenting at PCR Innovators Day 2019 in Paris
April 2019

Cavis presented the Wirecath at the PCR Innovators Day in Paris!

The congress is especially focused on novel and innovative technologies in the cardiovascular research field and precedes the major meeting EuroPCR. 491 professionals attended on the May 20th 2019. Our presentation is found here. We gained interest especially from clinicians and distributors.

Winner of EIT Health Headstart Funding Programme
July 2018

As one of the very winners, Cavis will be supported by the EIT Health Headstart Funding Programme 2018-2019 with a 50k€ grant.

The programme boosts SMEs in developing new products and services. Selected companies will receive funding for their product launch project and access to the EIT Health networks.

Sweden´s most prestigious innovation award received
September 2017

Cavis wins the regional SKAPA award in 2017!

The prize is Sweden´s most prestigious innovation award and shall support start-ups in developing their outstanding ideas. Since 1989, the prize is annually awarded by the SKAPA foundation in memory of Alfred Nobel.

Joining the UIC Accelerator program
January 2018

Cavis joins the Uppsala Innovation Centre (UIC) Accelerator program!

UIC is one of Sweden’s leading business incubators and is ranked by UBI Global as the world’s 4th best business incubator affiliated with a university. The incubator supports innovative startups and growth companies in their efforts to commercialize, scale-up and reach an international market.

Awarded by the Medtech4Health program
November 2016

The Swedish innovation agency welcomes Cavis in their Medtech4Health program with a 180k€ grant.

The program is focused on promoting innovative medical technologies. The program provides funding and ongoing support for the development of Cavis new product ideas.

Successful completion of animal study
April 2016

Cavis completed the proof-of-concept animal study showing a solid performance of the innovative pressure guidewire Wirecath.

The study was funded by Swedish innovation agency Vinnova and the business incubator Uppsala Innovation Centre.

Cavis Technologies incorporation
September 2015

Cavis Technologies was founded in Uppsala, Sweden.

We are an innovative start-up company supplying invasive cardiology care units with a unique device for improved control and safety.


Cavis Technologies was founded 2015. It’s an innovative start-up company supplying invasive cardiology care units with a unique device for improved control and safety.



Cavis Technologies AB

Kungsängsvägen 29A

75323 Uppsala


© 2018 Cavis Technologies AB - All Rights Reserved Information about cookies